DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

NEWS RELEASE

Released: December 23, 2009

Department of Defense Breast Cancer Research Program
Funding for Fiscal Year 2010

The Fiscal Year 2010 (FY10) Defense Appropriations Act provides $150 million to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact breast cancer research. The BCRP is administered by the US Army Medical Research and Materiel Command (USAMRMC) through the Office of Congressionally Directed Medical Research Programs (CDMRP).

The BCRP is providing the information in this pre-announcement to allow investigators time to plan and develop proposals. FY10 BCRP program announcements and application instructions for the following award mechanisms are anticipated to be posted on Grants.gov by February 2010, unless noted otherwise.

Award Mechanism Eligibility Key Mechanism Elements Funding
Concept Award (to be offered in April 2010) Investigators at all academic levels (or equivalent)
  • Supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to breast cancer
  • Supports high-risk studies that have the potential to reveal new avenues for investigation
  • Preliminary data not allowed
  • Maximum funding of $75K for direct costs (plus indirect costs)
  • Period of performance not to exceed 1 year
Era of Hope Scholar Award Independent, non-mentored investigators within 6 years of their last mentored position as of the application submission deadline
  • Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the "best and brightest" in their fields
  • Individuals should exhibit strong potential for leadership in the breast cancer community
  • Maximum funding of $2.5M for direct costs (plus indirect costs)
  • Period of performance not to exceed 5 years
Idea Award
  • Investigators at all academic levels (or equivalent)
  • Postdoctoral-level investigators are eligible and are encouraged to apply
  • Supports conceptually innovative, high-risk/high-reward research from all areas of basic, translational, clinical, behavioral, and epidemiological research
  • Innovation is the most important review criterion
  • Preliminary data not consistent with intent of the award mechanism; strength of proposal should not rely on preliminary data
  • Collaborative Option supports combining expertise of two Principal Investigators to more effectively address an innovative research question
  • Maximum funding of $375K for direct costs (plus indirect costs) Period of performance not to exceed 2 years
  • For Collaborative Option: Maximum funding of $550K for direct costs (plus indirect costs) Period of performance not to exceed 2 years
  • For Population-Based Studies: Maximum funding of $750K for direct costs (plus indirect costs) Period of performance not to exceed 4 years
Innovator Award Associate Professor or above (or equivalent)
  • Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field
  • Provides opportunity to pursue novel, visionary, high-risk ideas that could ultimately lead to the eradication of breast cancer
  • Maximum funding of $5M for direct costs (plus indirect costs)
  • Period of performance not to exceed 5 years
Inter-Institutional Training Award
  • Principal Investigator/Co-investigator(s): Faculty members with doctoral degrees who are at an institution that does not have an established breast cancer research program
  • Mentor(s): Must be part of an established breast cancer research program at the mentoring institution
  • Supports two or more faculty-level investigators at an organization that does not currently have a breast cancer research program to acquire mentored training in breast cancer research
  • Supports the establishment of a sustainable breast cancer research program at the applicant organization
  • Proposed research and training should lead to publication(s) and independent breast cancer research funding
  • Preproposal is required; proposal submission is by invitation only
  • Maximum funding of $1M for direct costs (plus indirect costs)
  • Period of performance not to exceed 4 years
Multi-Team Award
  • Three independent, faculty-level (or equivalent) investigators
  • Must include a basic investigator, a clinical investigator, and an investigator from any other area of expertise
  • Supports three innovative investigators and their research teams in a coordinated and integrated translational research effort to address a question of major importance in breast cancer
  • Teams must include consumer advocates
  • Multiple institutions must be involved
  • A clear plan for intensive collaboration among the teams must be demonstrated
  • Regular in-person meetings and on-site cross-training of investigators among the research teams will be required
  • Preproposal is required; proposal submission is by invitation only
  • Maximum funding of $300K for direct costs (plus indirect costs)
  • Period of performance not to exceed 3 years
Postdoctoral Fellowship Award
  • Principal Investigator: Graduate student enrolled in a PhD or MD/PhD program
  • No more than 2 years in the proposed research setting and no more than 4 years' postdoctoral research experience
  • Mentor or formal co-mentor: Must have breast cancer experience, to include current funding and publications
  • Supports the training of exceptionally talented recent doctoral graduates
  • Proposed research should be innovative and have the potential for high impact
  • Multidisciplinary training encouraged
  • Training program and mentorship should prepare the PI for an independent career at the forefront of breast cancer research
  • Maximum funding of $300K for direct costs (plus indirect costs)
  • Period of performance not to exceed 3 years
Predoctoral Traineeship Award
  • Principal Investigator: Graduate student enrolled in a PhD or MD/PhD program
  • Mentor or formal co-mentor: Must have breast cancer experience, to include current funding and publications
  • Supports the training of promising graduate students studying breast cancer research under the guidance of a designated mentor
  • The predoctoral trainee is considered the PI and should write the proposal with appropriate direction from the mentor
  • Training program and mentorship should facilitate development of the PI as a breast cancer researcher
  • Maximum funding of $120K for direct costs (plus indirect costs)
  • Period of performance not to exceed 3 years
Transformative Vision Award Investigators at all academic levels (or equivalent)
  • Supports research programs that have an extraordinary vision for dramatically transforming the prevention or treatment of breast cancer and a plan to test and implement the vision as quickly as possible
  • Focuses on achieving a visionary solution to a problem or question of overarching importance to breast cancer through an investigator-defined approach
  • Preproposal is required; proposal submission is by invitation only
  • Maximum funding of $12M for direct costs (plus indirect costs)
  • Period of performance not to exceed 5 years

All applications must conform to the final program announcements and application instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

A pre-application is required and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to application submission. Applications must be submitted through the federal government's single-entry portal, Grants.gov. Requests for email notification of the program announcements release may be sent to help@cdmrp.org. For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact: